The Lancet HIV· Anne E M Kamphuis, Nicolas Salvadori, Hilda Angela Mujuru, Mutsawashe Bwakura-Dangarembizi, Grace Paul Kisitu, Frank Matovu, Elizabeth Kaudha, Alice Mulindwa, Tom G Jacobs, Kanchana Than-in-at, Tim R Cressey, Alessandra Nardone, Marc Lallemant, Angela Colbers, David M Burger, UNIVERSAL1 trial team·· 2026-09-08AI 评分58
UNIVERSAL1 I/II 期试验:多替拉韦-恩曲他滨-替诺福韦艾拉酚胺分散片固定剂量方案用于 4 周以上 HIV 儿童 24 周结果
[Articles] Expediting a UNIVERSAL first-line regimen of a dolutegravir–emtricitabine–tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1–2, pharmacokinetic, safety, and antiviral activity trial
AI 导读
UNIVERSAL1 是一项 24 周、开放标签、单臂 I/II 期药代动力学、安全性与抗病毒活性试验,评估多替拉韦-恩曲他滨-替诺福韦艾拉酚胺固定剂量方案用于 4 周以上 HIV 感染儿童。
来源:The Lancet HIV · thelancet.com